Current perspectives on skeletal health and cancer progression across the disease continuum in breast cancer - The role of bisphosphonates

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Pre-clinical and clinical evidence suggest that bisphosphonates inhibit both bone resorption and cancer progression. New and updated analyses from several large, controlled studies in pre- and post-menopausal women with early stage breast cancer (BC) suggest that addition of bisphosphonates improves cancer-related outcomes, particularly in patients with a 'low-estrogen environment'. Further, preliminary clinical data suggest that bisphosphonate therapy may reduce circulating tumour cell numbers (a negative prognostic indicator of disease-free and overall survival) in patients with advanced/metastatic disease. These new findings warrant reconsideration of the therapeutic role of bisphosphonates in BC.

Original languageEnglish
Article number265
Journalecancermedicalscience
Volume6
Issue number1
DOIs
StatePublished - Aug 23 2012

Keywords

  • Bisphosphonates
  • Breast cancer
  • Treatment
  • Zoledronic acid

Fingerprint Dive into the research topics of 'Current perspectives on skeletal health and cancer progression across the disease continuum in breast cancer - The role of bisphosphonates'. Together they form a unique fingerprint.

Cite this